Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$53.82

-3.83 (-6.64%)

, ANTM

Anthem

$120.84

-1.06 (-0.87%)

13:13
10/12/16
10/12
13:13
10/12/16
13:13

Anthem says policy unchanged on Sarepta's Exondys 51, Bloomberg reports

Bloomberg cites an emailed comment from an Anthem spokesperson.

SRPT

Sarepta

$53.82

-3.83 (-6.64%)

ANTM

Anthem

$120.84

-1.06 (-0.87%)

  • 02

    Nov

  • 06

    Nov

SRPT Sarepta
$53.82

-3.83 (-6.64%)

10/07/16
BARD
10/07/16
NO CHANGE
Target $102
BARD
Outperform
Anthem policy does not mean insurer not covering Sarepta drug, says Baird
Baird analyst Brian Skorney noted Anthem (ANTM) has categorized Sarepta (SRPT) Duchenne muscular dystrophy drug Exondys 51 as "not medically necessary" in a new coverage policy, but he cautions this "does not mean that Anthem is not covering the drug." The analyst explains that the policy means prior authorization requirements may be stricter, but he "highly doubts" that eligible patients will be denied coverage. Skorney, who adds that other large insurers appear to have favorable coverage for the drug, keeps an Outperform rating and $102 price target on Sarepta shares.
10/05/16
ADAM
10/05/16
NO CHANGE
Target $28
ADAM
Buy
Summit Therapeutics price target raised to $28 from $14 at Canaccord
Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $68
PIPR
Overweight
Piper Jaffray ups Sarepta target to $68 on Summit deal
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics (SRPT) to $68 from $64 after the company licensed Summit Therapeutics' (SMMT) ezutromid to treat Duchenne Muscular Dystrophy in Europe, Turkey and the Commonwealth of Independent States. The deal is a smart way for Sarepta to capitalize on its lead in DMD with the recent FDA approval of Exondys51, Tenthoff tells investors in an intraday research note. His new price target of $68 reflects the value of ezutromid. Tenthoff reiterates an Overweight rating on Sarepta. The stock is up 1% to $61.61 in late morning trading. Summit is up 94%, or $8.17, to $16.82.
09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
ANTM Anthem
$120.84

-1.06 (-0.87%)

09/22/16
EVER
09/22/16
INITIATION
Target $133
EVER
Hold
Anthem initiated with a Hold at Evercore ISI
Evercore ISI initiated Anthem with a Hold and a $133 price target.
09/20/16
BOFA
09/20/16
NO CHANGE
BOFA
Anthem removed from US 1 List at BofA/Merrill
09/13/16
JEFF
09/13/16
DOWNGRADE
Target $138
JEFF
Hold
Anthem downgraded to Hold from Buy at Jefferies
Jefferies analyst David Windley downgraded Anthem (ANTM) to Hold from Buy saying the restoration of some of the company's expense cuts could limit 2017 earnings growth. "The belt-tightening also potentially signals under-investment in the platform," Windley tells investors in a research note. He sees a lack of catalysts for Anthem shares and cut his price target to $138 from $156. The health benefit company closed yesterday up $1.63 to $128.58. In Managed Care, Windley's top pick is UnitedHealth (UNH). The company has an attractive valuation and "best-in-class" management team, Windley argues. He has a Buy rating on UnitedHealth with a $163 price target.
08/25/16
COWN
08/25/16
NO CHANGE
COWN
Managed Care mergers unlikely to close, says Cowen
Cowen analyst Christine Arnold believes the current managed care mergers including Aetna (AET) and Humana (HUM) and Anthem (ANTM) and Cigna (CI) are unlikely to close. The analyst said the government's ability to appeal could extend the litigation process beyond the termination dates stipulated in the merger agreements. Arnold believes the Aetna/Humana merger has a better chance of closing relative to the Anthem/Cigna deal, but believes neither are likely to close.

TODAY'S FREE FLY STORIES

OCLR

Oclaro

$9.72

-1.25 (-11.39%)

20:45
02/22/17
02/22
20:45
02/22/17
20:45
Conference/Events
Oclaro management to meet with Jefferies »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 03

    Mar

GMS

GMS Inc.

$29.79

-0.52 (-1.72%)

20:32
02/22/17
02/22
20:32
02/22/17
20:32
Syndicate
GMS Inc. 6.95M share Secondary priced at $29.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

APA

Apache

$54.91

-0.98 (-1.75%)

, HRL

Hormel Foods

$37.30

-0.3 (-0.80%)

20:25
02/22/17
02/22
20:25
02/22/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

APA

Apache

$54.91

-0.98 (-1.75%)

HRL

Hormel Foods

$37.30

-0.3 (-0.80%)

KSS

Kohl's

PF

Pinnacle Foods

$54.63

-0.61 (-1.10%)

CHK

Chesapeake

$5.92

-0.16 (-2.63%)

CNK

Cinemark

$43.39

0.51 (1.19%)

AMCX

AMC Networks

$57.50

-0.19 (-0.33%)

W

Wayfair

$41.26

1 (2.48%)

SFM

Sprouts Farmers Markets

$19.00

-0.32 (-1.66%)

TREE

LendingTree

$112.15

-1.45 (-1.28%)

TXMD

TherapeuticsMD

$5.67

0.08 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 28

    Feb

  • 01

    Mar

  • 06

    Mar

  • 16

    Mar

  • 19

    Mar

  • 21

    Mar

  • 28

    Mar

  • 07

    May

  • 11

    May

FIT

Fitbit

$5.88

-0.16 (-2.65%)

20:14
02/22/17
02/22
20:14
02/22/17
20:14
Hot Stocks
Fitbit CEO says early adopter segment saturated, says exploring new form factors »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

SQ

Square

$15.04

0.41 (2.80%)

19:57
02/22/17
02/22
19:57
02/22/17
19:57
Upgrade
Square rating change  »

Square upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

FIT

Fitbit

$5.88

-0.16 (-2.65%)

19:50
02/22/17
02/22
19:50
02/22/17
19:50
Hot Stocks
Fitbit says paid $23M for Pebble assets »

Fitbit disclosed in its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

SBUX

Starbucks

$57.57

0.03 (0.05%)

19:34
02/22/17
02/22
19:34
02/22/17
19:34
Hot Stocks
Market researcher: Starbucks consumer perception dips after refugee hiring news »

Market researcher YouGov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

LB

Labarge

$58.13

0.43 (0.75%)

19:33
02/22/17
02/22
19:33
02/22/17
19:33
Hot Stocks
L Brands sees Q1 comps down high-single to low-double digits »

Sees Q1 Go-Forwards comps…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

LB

Labarge

$58.13

0.43 (0.75%)

19:32
02/22/17
02/22
19:32
02/22/17
19:32
Hot Stocks
L Brands sees FY17 comps down low-single digits »

Sees FY17 Go-Forward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

F

Ford

$12.67

-0.02 (-0.16%)

19:30
02/22/17
02/22
19:30
02/22/17
19:30
Conference/Events
Ford to host sales conference call »

Ford U.S. Sales Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

GTLS

Chart Industries

$38.51

-1.21 (-3.05%)

19:27
02/22/17
02/22
19:27
02/22/17
19:27
Hot Stocks
Chart Industries CEO Samuel Thomas named executive chairman »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$273.51

-3.88 (-1.40%)

19:24
02/22/17
02/22
19:24
02/22/17
19:24
Periodicals
SolarCity leased with risky homeowners, has ties to foreclosure cases, NYT says »

In "dozens of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

PRU

Prudential

$110.50

-0.72 (-0.65%)

, WFC

Wells Fargo

$58.36

0.11 (0.19%)

19:16
02/22/17
02/22
19:16
02/22/17
19:16
Hot Stocks
Prudential says could seek compensation from Wells Fargo over MyTerm products »

Prudential (PRU) stated…

PRU

Prudential

$110.50

-0.72 (-0.65%)

WFC

Wells Fargo

$58.36

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 13

    Apr

  • 06

    Jun

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

PSA

Public Storage

$226.24

-1.49 (-0.65%)

19:15
02/22/17
02/22
19:15
02/22/17
19:15
Earnings
Public Storage reports Q4 core FFO $2.65, consensus $1.89 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CS

Credit Suisse

$15.35

-0.13 (-0.84%)

19:10
02/22/17
02/22
19:10
02/22/17
19:10
Periodicals
Credit Suisse probed for potentially aiding tax evasion, WSJ says »

Less than three years…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

LZB

La-Z-Boy

$28.40

-1.05 (-3.57%)

19:09
02/22/17
02/22
19:09
02/22/17
19:09
Downgrade
La-Z-Boy rating change  »

La-Z-Boy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CLD

Cloud Peak

$5.68

-0.19 (-3.24%)

19:06
02/22/17
02/22
19:06
02/22/17
19:06
Syndicate
Cloud Peak 13.5M share Spot Secondary priced at $5.10 »

Credit Suisse, JPMorgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SNAP

Snap Inc

18:47
02/22/17
02/22
18:47
02/22/17
18:47
Periodicals
Snap Inc nears $200M ad deal, NY Post says »

Snap Inc is close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

SBLK

Star Bulk Carriers

$9.59

0.29 (3.12%)

18:40
02/22/17
02/22
18:40
02/22/17
18:40
Earnings
Star Bulk Carriers reports Q4 EPS (29c), consensus (28c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 22

    Mar

C

Citi

$60.62

0.07 (0.12%)

18:35
02/22/17
02/22
18:35
02/22/17
18:35
Periodicals
Citi forms regulatory affairs team in D.C., Bloomberg says »

Citi is forming a global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

PRAH

PRA Health

$59.98

-0.71 (-1.17%)

18:34
02/22/17
02/22
18:34
02/22/17
18:34
Earnings
PRA Health sees FY17 EPS $3.08-$3.18, consensus $2.96 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

FGL

Fidelity & Guaranty Life

$26.30

-0.1 (-0.38%)

, ATH

Athene Holding

$51.45

0.38 (0.74%)

18:32
02/22/17
02/22
18:32
02/22/17
18:32
Periodicals
Fidelity & Guaranty Life revives sale process, Insurance Insider says »

Fidelity & Guaranty…

FGL

Fidelity & Guaranty Life

$26.30

-0.1 (-0.38%)

ATH

Athene Holding

$51.45

0.38 (0.74%)

APO

Apollo Global

$22.25

0.05 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

PRAH

PRA Health

$59.98

-0.71 (-1.17%)

18:31
02/22/17
02/22
18:31
02/22/17
18:31
Earnings
PRA Health sees Q1 EPS 57c-62c, consensus 67c »

Sees Q1 service revenues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NBR

Nabors Industries

$15.44

0.01 (0.06%)

18:30
02/22/17
02/22
18:30
02/22/17
18:30
Earnings
Nabors Industries reports Q4 EPS ($1.17) with items »

Q4 EPS includes 87c in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

AXGN

AxoGen

$10.50

-0.1 (-0.94%)

18:28
02/22/17
02/22
18:28
02/22/17
18:28
Earnings
AxoGen reiterates FY17 revenue growth view of at least 40% »

Management reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 14

    Mar

  • 21

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.